Which tumor tissue chip with survival information is complete, and is the data updated in a timely manner?

With more than 150 chips with survival data, there are few options in stock. Most of them need to be semi-customized or customized. The supply cycle is generally 4-8 weeks. If the merchant says that it will ship in 1 week, it is necessary to confirm whether it is an existing finished product but the follow-up is older. The cost is usually reported according to the number of points in the array, the complexity of the data field, and whether to make up for the follow-up. The domestic price is generally lower than the import, but the customized markup is obvious. With a limited budget, you can choose large chips in stock + organize and follow up by yourself, but the workload is large and the data quality is difficult to control; if the data can be supplemented after sales, it will be acceptable to spend a little more. It is recommended to take 2-3 quotations, focusing on comparing the number of effective cases, events, and follow-up deadlines, rather than looking at the sticker price alone.

Multi-cancer TMAs with more than 150 cases of survival information and field specifications can be focused on platforms such as Shanghai Xinchao and Outdo in China, and US Biomax and Pantomics in foreign countries. However, the follow-up data of imported chips are often relatively simple or the follow-up deadline is relatively early. The key is not fame, but the ability to provide fields that meet the study endpoints: TNM staging (clear AJCC version), survival time, survival status, censoring definition, and follow-up cut-off date. The data dictionary and sample list are required to be sent, and 5-10 cases are first drawn to check the pathology report. Some domestic platforms can make up follow-up according to the project, but the period and cost need to be confirmed separately.

Most commercial spot chips do not provide follow-up updates. Some domestic customized or semi-customized suppliers can agree on data replenishment or cleaning services at the time of signing the contract, such as postponing the follow-up deadline by one year, unifying the TNM staging version, and making up missing fields. It is recommended to write the number of data updates, format, delivery time, and acceptance criteria into the contract to avoid postponement. Note that label uniformity is more important than data volume, and subsequent analysis will be difficult if the TNM version is mixed; you can first re-label the supplier according to AJCC version 8, or provide original pathological information for yourself to unify.

Get the chip to check the lattice diagram and HE first, mark which points are missing, necrosis, or insufficient tumor cells, and remove them when combining with IHC analysis. Survival data should not only look at the total number of 150 cases, but also at whether the effective number of cases and the number of events of the target cancer species are sufficient, especially when the number of events is too small for prognostic stratification, which will be unstable. You can stain one or two indicators that you are familiar with, verify the chip antigen preservation and data quality, and then decide whether to put on the full set. The survival time unit in the clinical follow-up field should be confirmed whether it is month or day, and whether the survival status is verified by death registration or telephone follow-up.